BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 23026237)

  • 21. Expression, purification, and characterization of an immunotoxin containing a humanized anti-CD25 single-chain fragment variable antibody fused to a modified truncated Pseudomonas exotoxin A.
    Wang H; Dai J; Li B; Fan K; Peng L; Zhang D; Cao Z; Qian W; Wang H; Zhao J; Guo Y
    Protein Expr Purif; 2008 Mar; 58(1):140-7. PubMed ID: 17950620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment.
    Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I
    J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis.
    Gao W; Tang Z; Zhang YF; Feng M; Qian M; Dimitrov DS; Ho M
    Nat Commun; 2015 Mar; 6():6536. PubMed ID: 25758784
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel recombinant anti-HER2/neu immunotoxin: design and antitumor efficiency.
    Sokolova EA; Zdobnova TA; Stremovskiy OA; Balalaeva IV; Deyev SM
    Biochemistry (Mosc); 2014 Dec; 79(12):1376-81. PubMed ID: 25716732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel composite immunotoxin that suppresses rabies virus production by the infected cells.
    Mareeva T; Wanjalla C; Schnell MJ; Sykulev Y
    J Immunol Methods; 2010 Feb; 353(1-2):78-86. PubMed ID: 19932697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generation of Potent Anti-HER1/2 Immunotoxins by Protein Ligation Using Split Inteins.
    Pirzer T; Becher KS; Rieker M; Meckel T; Mootz HD; Kolmar H
    ACS Chem Biol; 2018 Aug; 13(8):2058-2066. PubMed ID: 29920062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.
    Waldron NN; Kaufman DS; Oh S; Inde Z; Hexum MK; Ohlfest JR; Vallera DA
    Mol Cancer Ther; 2011 Oct; 10(10):1829-38. PubMed ID: 21862685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy.
    Chen H; Gao J; Lu Y; Kou G; Zhang H; Fan L; Sun Z; Guo Y; Zhong Y
    J Control Release; 2008 Jun; 128(3):209-16. PubMed ID: 18450313
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
    Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
    Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant immunotoxins containing the VH or VL domain of monoclonal antibody B3 fused to Pseudomonas exotoxin.
    Brinkmann U; Lee BK; Pastan I
    J Immunol; 1993 Apr; 150(7):2774-82. PubMed ID: 8454854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A human recombinant autoantibody-based immunotoxin specific for the fetal acetylcholine receptor inhibits rhabdomyosarcoma growth in vitro and in a murine transplantation model.
    Gattenlöhner S; Jörissen H; Huhn M; Vincent A; Beeson D; Tzartos S; Mamalaki A; Etschmann B; Muller-Hermelink HK; Koscielniak E; Barth S; Marx A
    J Biomed Biotechnol; 2010; 2010():187621. PubMed ID: 20204062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
    Weldon JE; Pastan I
    FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa.
    Shadman Z; Farajnia S; Pazhang M; Tohidkia M; Rahbarnia L; Najavand S; Toraby S
    BMC Infect Dis; 2021 Mar; 21(1):300. PubMed ID: 33761869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Studies of the expression, purification, renaturation and biologic activity of an anti-CEA immunotoxin].
    Yang H; He D; Chao K; Lin Q; You S; Huang HL
    Sheng Wu Gong Cheng Xue Bao; 2004 May; 20(3):348-51. PubMed ID: 15971603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer.
    Bühler P; Wetterauer D; Gierschner D; Wetterauer U; Beile UE; Wolf P
    Anticancer Res; 2010 Sep; 30(9):3373-9. PubMed ID: 20944111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2-specific recombinant immunotoxin 4D5scFv-PE40 passes through retrograde trafficking route and forces cells to enter apoptosis.
    Sokolova E; Guryev E; Yudintsev A; Vodeneev V; Deyev S; Balalaeva I
    Oncotarget; 2017 Mar; 8(13):22048-22058. PubMed ID: 28423549
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice.
    Kreitman RJ; Hansen HJ; Jones AL; FitzGerald DJ; Goldenberg DM; Pastan I
    Cancer Res; 1993 Feb; 53(4):819-25. PubMed ID: 8428363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systematic comparison of single-chain Fv antibody-fusion toxin constructs containing Pseudomonas Exotoxin A or saporin produced in different microbial expression systems.
    Della Cristina P; Castagna M; Lombardi A; Barison E; Tagliabue G; Ceriotti A; Koutris I; Di Leandro L; Giansanti F; Vago R; Ippoliti R; Flavell SU; Flavell DJ; Colombatti M; Fabbrini MS
    Microb Cell Fact; 2015 Feb; 14():19. PubMed ID: 25889802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.
    Brinkmann U; Gallo M; Brinkmann E; Kunwar S; Pastan I
    Proc Natl Acad Sci U S A; 1993 Jan; 90(2):547-51. PubMed ID: 8421689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. EGF ligand fused to truncated Pseudomonas aeruginosa exotoxin A specifically targets and inhibits EGFR‑positive cancer cells.
    Hashimi SM; Grant B; Alqurashi N; Alowaidi F; Wei MQ
    Oncol Rep; 2018 Nov; 40(5):2690-2697. PubMed ID: 30226622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.